Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generex Biotechnology's subsidiary, Antigen Express, has signed an agreement with The Scripps Research Institute to test the potency of a modified DNA vaccine for treatment of various forms of cancer.
Subscribe to our email newsletter
Scripps, based in La Jolla, California, is one of largest private, non-profit research organizations in the US. The investigation will follow up on earlier studies at Antigen Express showing that the modifications being tested led to a stronger immune response to therapeutic antigens encoded by DNA vaccines than were otherwise observed.
Antigen Express is working to develop technology that increases the antigen-specific stimulation of T helper cells. Particularly in the field of cancer immunotherapy, the importance of T helper stimulation has been demonstrated both in preclinical animal models and in the clinic.
Antigens synthesized within cells, as with DNA vaccines, bypass the mechanisms for T helper stimulation, but, by adding genetic elements to DNA vaccines, Antigen Express has developed a simple method to force antigens synthesized within cells to stimulate T helper cells.